What does this research mean for the field?

Cefepime/enmetazobactam is an effective treatment for complicated urinary tract infections and pyelonephritis, particularly against ESBL-producing Enterobacterales, demonstrating superior composite cure rates compared to piperacillin/tazobactam. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to evaluate cefepime/enmetazobactam's effectiveness against multidrug-resistant gram-negative infections, particularly cUTIs.

June 20, 2026Anti-Infective Agents

Cefepime/Enmetazobactam: A Novel β-Lactam/β-Lactamase Inhibitor Combination for Multidrug-Resistant Gram-Negative Infections

View Full Paper

Ask AI

Bookmark

Authors

PPPonmani PKarpagam Academy of Higher Education SZS ZamanNewcastle University Medicine Malaysia RSRatnesh SinhaManipal Academy of Higher Education

Discussion

Member takes

Implication

Narrative review demonstrates cefepime/enmetazobactam's efficacy for complicated urinary tract infections, indicating potential in AMR management.

Key Points

The aim is to evaluate cefepime/enmetazobactam's effectiveness against multidrug-resistant gram-negative infections, particularly cUTIs.
Narrative review of phase 1–3 trials, in vitro studies, and pharmacokinetic data
Comparison of cefepime/enmetazobactam against other treatments in cUTIs
Network meta-analyses for evaluating outcomes based on existing trials
Cefepime/enmetazobactam demonstrated a superior composite cure rate of 79.1% compared to 58.9% with piperacillin/tazobactam (difference 21.2%) in the ALLIUM trial (n=1034)
Susceptibility to cefepime increased from 2% to 98% against ESBL-producing Enterobacterales due to enmetazobactam's activity
Network meta-analyses indicated outcomes comparable to carbapenems with similar safety profiles, mainly regarding hepatic and infusion events.

Cite This Study

P et al. (2026) studied this question.

synapsesocial.com/papers/6a362f63db0793dc1a536dd1 https://doi.org/10.2174/0122113525464516260531163314

View Full Paper

Ask AI

Bookmark

Implication

Narrative review demonstrates cefepime/enmetazobactam's efficacy for complicated urinary tract infections, indicating potential in AMR management.

Cefepime/Enmetazobactam: A Novel β-Lactam/β-Lactamase Inhibitor Combination for Multidrug-Resistant Gram-Negative Infections

Discussion

Member takes

Implication

Key Points

Cite This Study

Cefepime/Enmetazobactam: A Novel β-Lactam/β-Lactamase Inhibitor Combination for Multidrug-Resistant Gram-Negative Infections

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider